Novartis AG ADR (NYSE: NVS) on Tuesday, plunged -0.65% from the previous trading day, before settling in for the closing price of $116.70. Within the past 52 weeks, NVS’s price has moved between $96.06 and $120.92.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 1.16% over the last five years. The company achieved an average annual earnings per share of 11.01%. With a float of $1.90 billion, this company’s outstanding shares have now reached $1.96 billion.
The firm has a total of 75883 workers. Let’s measure their productivity. In terms of profitability, gross margin is 75.4%, operating margin of 29.79%, and the pretax margin is 28.22%.
Novartis AG ADR (NVS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – General industry stocks is more important than anything else. The insider ownership of Novartis AG ADR is 0.00%, while institutional ownership is 7.34%. The most recent insider transaction that took place on May 23 ’25, was worth 1,690,181. Before that another transaction happened on Apr 30 ’25, when Company’s Officer proposed sale 1,212 for $113.28, making the entire transaction worth $137,297.
Novartis AG ADR (NVS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.90% during the next five years compared to 13.99% growth over the previous five years of trading.
Novartis AG ADR (NYSE: NVS) Trading Performance Indicators
Novartis AG ADR (NVS) is currently performing well based on its current performance indicators. A quick ratio of 0.61 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.25. Likewise, its price to free cash flow for the trailing twelve months is 12.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.39, a number that is poised to hit 2.31 in the next quarter and is forecasted to reach 9.02 in one year’s time.
Technical Analysis of Novartis AG ADR (NVS)
Analysing the last 5-days average volume posted by the [Novartis AG ADR, NVS], we can find that recorded value of 1.64 million was lower than the volume posted last year of 2.17 million. As of the previous 9 days, the stock’s Stochastic %D was 94.45%. Additionally, its Average True Range was 1.93.
During the past 100 days, Novartis AG ADR’s (NVS) raw stochastic average was set at 95.03%, which indicates a significant increase from 93.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 20.46% in the past 14 days, which was lower than the 24.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $110.51, while its 200-day Moving Average is $109.07. Now, the first resistance to watch is $116.40. This is followed by the second major resistance level at $116.86. The third major resistance level sits at $117.42. If the price goes on to break the first support level at $115.38, it is likely to go to the next support level at $114.82. Now, if the price goes above the second support level, the third support stands at $114.36.
Novartis AG ADR (NYSE: NVS) Key Stats
Market capitalization of the company is 220.01 billion based on 2,112,422K outstanding shares. Right now, sales total 51,722 M and income totals 11,941 M. The company made 13,620 M in profit during its latest quarter, and 3,606 M in sales during its previous quarter.
